Study QSOX1 as a colon cancer biomarker
Part of Cancer, Digestive system clinical trials.
This study looks at a lab marker called QSOX1 to see how it may relate to colon cancer. It may help doctors better detect or assess colon cancer, especially when compared with the appropriate cancer diagnosis data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon cancer based on a colonoscopy and tissue pathology test
- You have not had any treatment (local or whole-body treatment) before your operation
- Your medical records and clinical data are complete for the study
- You do not have colon conditions that mimic colon cancer (like ulcerative colitis, colon adenoma, or colon polyps)
- You do not have any other type of cancer besides colon cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
This study looks at a new blood test that may help doctors better understand how far colon cancer has spread. By testing a sample of your blood (taken before surgery), researchers hope to find patterns that predict the stage of cancer and help guide treatment decisions.
This study follows people with colon cancer over time to learn how treatments and health changes relate to outcomes. You may be invited if your care plan includes FOLFOX and you meet certain genetic and medical history requirements.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy (XELOX) given before surgery for Stage III colon cancer that is pMMR or MSS. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.